
New developments in CLL



Javier Pinilla-Ibarz, MD, PhD. Senior Member Head of Lymphoma section and Director of Immunotherapy Malignant Hematology Department




The dilemma continue between long term therapy vs fixed duration



Author'slide

Several Covalent BTKi to Consider With Differences in BTKi Specificity, MOA, and Potential for Off-Target Effects



Key Clinical Trials of 1st-Generation BTKi Ibrutinib in TN CLL

RESONATE-2¹

- Aged ≥65 years
- Non-del(17p)
- Ibrutinib vs Clb
- With up to 7 years of follow up, median PFS was not reached vs 15.0 months
- 6.5-year PFS: 61% vs 9%
- 6.5-year PFS by IGHV status
 - Mut: 67% vs 18%
 - Unmut: 62% vs 2%
- 6.5-year PFS by del(11q) status
 - With: 60% vs 0%
 - Without: 67% vs 13%

illuminate²

- Aged >65 years or ≤65 years with comorbidities
- lbrutinib + G vs Clb + G
- With a median follow-up of 31.3 months, median PFS was significantly longer with lbr+G vs Clb+G (NR vs 19.0 months; HR 0.23; *P*<0.0001)
- 30-month PFS was 79% vs 31%


ECOG E1912³⁻⁴

- Aged >70 years
- Non-del(17p)
- Ibrutinib + R (IR) vs FCR
- With a median follow-up of 70 months, 5-year PFS was 78% vs 51%, respectively (P<0.0001)
- PFS with IR vs FCR was statistically significant in *IGHV*mut (HR 0.27, *P*=0.001) and -unmut (HR 0.27, *P*<0.001) patients
- 5-year OS was 95% vs 89%, respectively (*P*=0.018)

Alliance (A041202)⁵

- Aged \geq 65 years
- BR (Arm 1) vs lbr (Arm 2) vs
 lbr + R (Arm 3)
- With a median follow-up of 55 months, median PFS was 44 months with Arm 1 and not reached with the others
 - Arm 2 vs 1: HR 0.36, 95%
 CI 0.26-0.52, P<0.0001
 - Arm 3 vs 1: HR 0.36, 95%
 CI 0.25-0.51, P<0.0001
 - Arm 3 vs 2: HR 0.99, 95%
 CI 0.66-1.48, P=0.96
- There were no significant differences in OS among the arms (P=0.49)

Initiating 1L Ibrutinib in Patients with CLL Improves Overall Survival Outcomes to Rates Approximating an Age-Matched Population of ≥65



aData after 96 months is not represented in the KM curve; bData after 144 months is not represented in the KM curve

Key Phase 3 Clinical Trials of 2nd-Generation BTKi in TN CLL


Acalabrutinib: ELEVATE-TN^{1,2}

- Aged ≥65 years, or younger with CIRS score >6 or CrCl <70 mL/min; del(17p) included
- Arms
 - Acalabrutinib vs
 - Acalabrutinib + Obin vs
 - Clb + O
- Improved PFS with acalabrutinib ± O
 - Median PFS (median follow-up: 58.2 months) was significantly longer for A-arms vs Clb+O (NR vs 27.8 months)
 - A+O vs Clb+O: HR 0.11 (95% Cl, 0.07-0.16)
 - A vs Clb+O: HR: 0.21 (95% Cl, 0.15-0.30)
 - Estimated 60-month PFS: 84% and 72% for A+O and A


Zanubrutinib: SEQUOIA^{3,4}

- Aged ≥65 years or unsuitable for FCR
- Non-del(17p) arms
 - Zanubrutinib vs
 - BR
- Del(17p) arms
 - Zanubrutinib
- Improved PFS with zanubrutinib
 - Median PFS (median follow-up: 43.7 months) was significantly longer for zanubrutinib vs BR (NR vs 42.2 months; HR 0.30 [95% CI, 0.21-0.43]; P<.0001)
 - Estimated 42-month PFS: 82.4% vs 50.0% for zanubrutinib vs BR

SEQUOIA: PFS



SEQUOIA: Survival Outcomes




Fixed duration, doublets and triplets combinations

CLL14: Venetoclax. +Obinutuzumab in TN CLL


CLL14


- CIRS score >6 and/or CrCl <70 mL/min
- *TP53*mut/del(17p) included
- Arms
 - VenG vs
 - Clb + G
- Median follow-up reached: 76.4 months
- Median PFS: 76.2 vs 36.4 months
 - 6-year PFS: 53.1% vs 21.7%
 - HR 0.40 (95% Cl, 0.31-0.52); P<0.0001
- Median OS not reached
 - 6-year OS: 78.7% vs 69.2%
 - HR 0.69 (95% Cl, 0.48-1.01); P=0.05



CLL14: PFS

PFS by TP53 Status





Al-Sawaf O, et al. EHA 2023. Abstract S145.

Ongoing Phase 2/3 Studies With BTKi Doublets for TN CLL

Ibrutinib + venetoclax (IV)

- IV in TN CLL (cohort 2) with high-risk features (phase 2, reported)¹⁻³
- IV vs FCR in TN CLL without del(17p) or TP53mut (phase 2, ongoing)⁴
- CAPTIVATE: IV in TN CLL (FD and MRD-guided cohorts) (phase 2, reported)⁵⁻⁷
- CLL17: I vs IV vs VO in TN CLL⁸ (ongoing)
- GLOW: IV vs G-Clb in TN CLL without del(17p) or TP53mut⁹ (reported)

Acalabrutinib + venetoclax (AV)

- AO vs AV in TN CLL without del(17p), *TP53*mut, or complex karyotype (phase 2, ongoing)¹⁰
- AV in TN CLL in patients at high risk of infection (phase 2, ongoing)¹¹
- MAJIC: AV vs VO in TN CLL (all-comers, ongoing)¹²


Zanubrutinib + venetoclax (ZV)

• **SEQUOIA:** Zanubrutinib + venetoclax (Arm D) vs zanubrutinib (Arm C) in TN CLL with del(17p) or *TP53* mut¹³ (reported)

1. NCT02756897. 2. Jain N, et al. *N Engl J Med*. 2019;380(22):2095-2103. 3. Jain N, et al. *JAMA Oncol*. 2021;7(8):1213-1219. 4. NCT04010968. 5. NCT02910583. 6. Wierda WG, et al. *J Clin Oncol*. 2021;39(34):3853-3865. 7. Tam CS, et al. *Blood*. 2022;139(22):3278-3289. 8. NCT04608318. 9. NCT03462719. 10. NCT05336812. 11. NCT03868722. 12. NCT05057494. 13. NCT03336333.

Phase 2 CAPTIVATE Study

 CAPTIVATE (PCYC-1142) is an international, multicenter phase 2 study evaluating first-line treatment with 3 cycles of ibrutinib followed by 12 cycles of combined ibrutinib + venetoclax that comprises 2 cohorts: MRD and FD



■ Results from the MRD cohort demonstrated uMRD in more than two-thirds of patients treated with 12 cycles of ibrutinib + venetoclax (PB, 75%; BM, 68%), and 30-month PFS rates of ≥95% irrespective of subsequent MRD-guided randomized treatment¹

CAPTIVATE FD Cohort: 4 Follow up - Deep And Durable Responses


Patients, %


- Best ORR was 96%
- Median DOR was not reached for responding patients (n=153)
- Median duration of CR was not reached (n=93); the 36-month landmark estimate for durable CR was 80% (95% CI 69–87)

100 12 months posttreatment 24 months posttreatment 90 36 months posttreatment 80 70 60 60% 50 54% 52% 49% 48% 44% 40 43% 36% 30 30% 20 10 40/81 69/145 60/136 8/22 6/20 49/82 32/75 80/148 2/23 0 del(17p)/TP53 mutated Unmutated IGHV All treated patients


CR Rate Over Time in Evaluable, All-Treated Patients

CAPTIVATE FD Cohort: 4y follow up Progression-Free and Overall Survival^{1,2}





CAPTIVATE Fixed-Dose Cohort 4-yr Update: PFS by MRD in PB



Landmark PFS rates at 48 months in patients who had uMRD in PB 3 months posttreatment were higher (90% than those with detectable MRD in PB 3 months posttreatment (66%)

·J

Retreatment Data From CAPTIVATE: 4-yr Update

To date, 19 patients who have progressed after completing fixed-duration ibrutinib + venetoclax (in either the FD or MRD cohort placebo arm) have initiated retreatment with ibrutinib; the median (range) retreatment duration is 11.1 (0–38.6) months


							Response to
							retreatment
					Response to FD		with
Patient	Baseline high risk features ^a				ibrutinib + venetoclax ^a		ibrutinib
	del(17p)	TP53	ulGHV	Complex	PFS	Best	Best
		mutated		karyotype	(months)	response	Response
1	No	No	Yes	Unknown	38.6	CR	CR
2	No	No	Yes	No	20.3	PR	PR
3	No	No	Yes	No	19.4	PR	PR
4	No	No	Yes	No	44.2	CR	PR
5	No	No	Yes	Yes	38.6	CR	PR
6	No	No	Yes	No	27.4	PR	PR
7	No	No	Yes	Yes	38.6	PR	PR
8	No	No	Yes	Yes	27.6	CR	PR
9	Yes	No	No	No	28.5	CRi	PR
10	Yes	No	Yes	Yes	16.6	PR	PR
11	No	No	Yes	No	36.5	CR	PR
12	No	No	No	No	27.4	PR	PR
13	No	No	No	Yes	22.0	PR	PR
14	No	No	No	Yes	30.4	PR	PR
15	No	No	Yes	Yes	38.6	CR	PRL
16	No	No	Yes	No	39.6	PR	SD
17	Yes	Yes	Yes	Yes	48.8	PR	PD⁵

Response data are available for 17 of these patients:

- CR, n=1
- PR, n=13
- PR with lymphocytosis, n=1
- Stable disease, n=1
- PD, n=1^b

GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Frontline CLL

International, open-label, randomized phase III trial




*Ramp-up from 20 to 400 mg over 5 wk starting in cycle 4.

- Primary endpoint: PFS per IRC
 - 71 PFS events to detect effect size with HR of 0.5 (80% power, 2-sided α = 0.05)
- Key secondary endpoints: uMRD in BM, CR rate per IRC, ORR per IRC, OS, safety
- 46 months median follow up

Nieman et al. ASH 2022


Superior PFS (by IRC) With I+V Versus Clb+O Was Maintained With Median 46 Months of F/u




Niemann, et al., ASH 2022;

GLOW: PFS by IGHV Mutational Status

(Elderly/Unfit, 12-mo Fixed Duration)




- Impact of IGHV status on PFS was more pronounced with Clb+O
- > 90% of patients in the I+V arm did not require subsequent treatment at 3.5 years:
 - 91.5% for uIGHV
 - 93.5% for mIGHV



- Estimated PFS at 2 years post-treatment for **uIGHV** CLL: - 90% for uMRD at EOT+3 vs 67% for MRD $\ge 10^{-4}$
- Estimated PFS at 2 years post-treatment for mIGHV CLL:
 > 90% regardless of MRD status at EOT+3

Niemann et al. ASH 2022

I+V Improved OS Versus Clb+O With 4 Years of Study Follow-up




^aCause and number (I+V arm, Clb+O arm) of "other" deaths: general/unknown (4, 5), cardiac (2, 4), CNS (2, 3), neoplasm (1, 3), euthanasia (1, 0), hepatobiliary (0, 1), respiratory (0, 1).

Median F/u 46 Months

Zanubrutinib-Venetoclax Combination Is Active in Del(17p)/TP53 CLL


SEQUOIA Arm D Tested Zanubrutinib-Venetoclax in High-Risk CLL¹

Of 36 evaluable patients, 14 were treated with the combination therapy for at least 12 months



1. Tedeschi A et al. ASH 2021. Abstract 67.

MAJIC Phase 3 Study Will Test Acalabrutinib-Venetoclax Combination in Patients With CLL/SLL¹



1. Davids MS et al. ASH 2021. Abstract 1553.

Ongoing Phase 2/3 Studies With BTKi Triplets for TN CLL

Ibrutinib + venetoclax + obinutuzumab (IVO)

- IVO in TN CLL with del(17p) or TP53mut (phase 2, ongoing)¹
- IO±V in patients with TN CLL <70 years of age without del(17p)² (ongoing)
- IO \pm V in patients with TN CLL \ge 65 years of age³ (ongoing)
- Alliance A041702: IO±V in patients with TN CLL ≥70 years of age^{4,5} (reported)
- GAIA-CLL13: IVO vs VO vs VR vs CIT in TN CLL without TP53 aberrations^{6,7} (reported)

Acalabrutinib + venetoclax ± obinutuzumab (AVO)


- AVO in TN CLL (cohort 2: with del[17p] or TP53mut) (phase 2, reported)^{8,9}
- AVO vs VO in TN CLL with del(17p), TP53mut, or complex karyotype¹⁰ (ongoing)
- AV±O vs FCR/BR in TN CLL without del(17p) or TP53mut¹¹ (ongoing)

Zanubrutinib + venetoclax + obinutuzumab (ZVO)

- BOVen: ZVO in TN CLL (phase 2, reported)^{12,13}
- BruVenG: ZV with response-based obinutuzumab in TN CLL (phase 2, ongoing)¹⁴


1. NCT02758665. 2. NCT03701282. 3. NCT03737981. 4. NCT03737981. 5. Woyach JA, et al. ASCO 2023. Abstract 7500. 6. NCT02950051. 7. Eichhorst B, et al. *N Engl J Med*. 2023;388:1739-1754. 8. NCT03580928. 9. Davids MS, et al. *Lancet Oncol*. 2021;22(10):1391-1402. 10. NCT05197192. 11. NCT03836261. 12. NCT03824483. 13. Soumerai JD, et al. *Lancet Haematol*. 2021;8(12):e879-e890. 14. NCT05650723.

GAIA-CLL13 Phase 3 Trial of First-Line Venetoclax Combinations in Fit Patients With CLL Without *TP53* Aberrations




- uMRD in PB at month 15
 - VO was superior to CIT (86.5% [97.5% CI, 80.6-91.1] vs 52.0%
 [97.5% CI, 44.4-59.5]; P<0.001)
 - VOI was superior to CIT (92.2% [97.5% CI, 87.3-95.7);
 P<0.001)
 - No significant difference between VR and CIT (57.0% [97.5% CI, 49.5-64.2]; *P*=0.32)

Eichhorst B, et al. N Engl J Med. 2023;388:1739-1754.



- PFS after a median follow-up of 38.8 months (IQR, 32.7-46.1)
 - VOI was superior to CIT (HR 0.32 [97.5% CI, 0.19-0.54]; P<0.001)
 - VO was superior to CIT (HR 0.42 [97.5% CI, 0.26-0.68]; P<0.001)
 - No significant difference between VR and CIT (HR 0.79 [97.5% CI, 0.53-1.18]; *P*=0.18)

Alliance A041702 Phase 3 Trial of IO±V in Patients With TN CLL (≥70 years of age)



IVO

233

187

152

101

69

39

- In this study, IVO is not superior to IO for the initial treatment of older patients with CLL
- COVID 19 may have significantly altered these results, with data suggesting a death imbalance for patients treated with venetoclax
- At this follow-up, PFS with IVO is not impacted by MRD or response status at end of 14 cycles
- Long-term follow-up of this study will be critical to determine whether some patients benefit from IVO


9

5

22

CLL2-GIVe: An Induction/Maintenance Approach Appears Feasible in High-Risk TN CLL¹


CLL2-GIVe study: Time limited first-line therapy in CLL with del(17p)/TP53mut




1. Huber H et al. Blood. 2022;139:1318-1329.

Time to OS, mo


40-Month Follow-Up From the Phase 2 Trial of BOVen (Zanubrutinib, Obinutuzumab, and Venetoclax) in TN CLL/SLL



 400-fold MRD reduction at C5D1 associated with 100% MRD-neg at 8 months




MRD-Free Survival in BM uMRD Patients (n=46)




Relapsed/Refractory and BTK mutational profile

ELEVATE-RR: IRC-Assessed PFS




ALPINE: PFS - ITT Population



MAIC: Is Ibrutinib Performing Historically?

Kaplan-Meier PFS estimates of ibrutinib-treated patients: RESONATE (adjusted population) vs ALPINE (published data)



mPFS:


RESONATE (adjusted) vs **ALPINE** 40.7 months vs 34.2 months HR 0.57 (CI 0.39-0.84)

RESONATE (adjusted) vs **ELEVATE-RR** 41.2 months vs 44 months HR: 1.15 (CI 0.46-1.31)

Due to variations inherent to manual data collection, there was a discrepancy (<1%) between the numbers of identified and published censoring events. This discrepancy is not likely to affect the conclusions.

MAIC: PFS by Investigator assessment in pooled acalabrutinib cohort compared with zanubrutinib


INV-PFS in Pooled Acalabrutinib Cohort vs Zanubrutinib



CI, confidence interval; ESS, effective sample size; HR, hazard-ratio; INV-PFS, investigator-assessed progression-free survival. Source: Kittai et al. Abstract 7540, ASCO 2023.


- Post-matching ESS of the pooled acalabrutinib arm from ASCEND and ELEVATE-RR was 130 (32% of the original pooled arm)
- There was no difference in INV-PFS between the pooled acalabrutinib cohort and zanubrutinib (HR 0.92; 95% CI 0.64–1.34)

Effect of C481S Mutation of BTK on BTKi Binding






Diverse BTK mutations cause resistance to covalent BTK inhibitors




Montoya et al ASH 2022

EMERGENT MUTATIONS AT THE TIME OF PROGRESSION IN PATIENTS TREATED WITH ACALABRUTINIB OR IBRUTINIB



BID, twice a day; QD, once a day. *P<0.05 per Fisher's Exact Test. Patients could have been included in >1 mutation category but were counted only once in a given single mutation category. Source: Woyach et al. Abstract 163. ICML 2023.

ELEVATE RR: BTK MUTATION VARIANT DISTRIBUTION BY TREATMENT ARM



BTK Leu528Trp Mutations in Patients with CLL on Zanubrutinib

- Consecutive samples at Peter MacCallum (AUS); N=37
- BTK Leu528Trp mutations were significantly enriched at time of PD for zanubrutinib versus ibrutinib:
 - **54%** [7/13] vs **4%** [1/24] (p=0.001)
- Other studies have shown that Leu528Trp mutations are rarely seen with ibrutinib

BTKi mutations detected in a cohort of patients with disease progression during BTKi treatment


	Number of patients carrying the mutations				
	Ibrutinib-treated patients (n = 24)	Zanubrutinib-treated patients (n =13)	Total	P	
Cys481 codon mutations	24	10	34	.03	
Leu528Trp	1	7	8	.001	

Both patients with Leu528Trp mutations treated with pirtobrutinib had poor responses


Kinase-dead BTK Leu528Trp mutation is enriched in patients with CLL progressing on zanubrutinib versus ibrutinib, which has potential implications for choice of BTK inhibitor and subsequent therapies, like pirtobrutinib, where this mutation is suspected to confer resistance

Piers Blombery, Ella R. Thompson, Thomas E. Lew, Ing Soo Tiong, Rory Bennett, Chan Y. Cheah, Katharine Louise Lewis, Sasanka M. Handunnetti, Chloe Pek Sang Tang, Andrew Roberts, John F. Seymour, Constantine S. Tam; Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. *Blood Adv* 2022; 6 (20): 5589–5592.

Covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) require WT BTK for activity




LOXO-305 is a non-covalent BTK inhibitor that is potent against both WT and C481-mutant BTK




Mato et al ASH 2022

Pirtobrutinib Efficacy in CLL/SLL Patients who Received Prior BTKi Treatment




Mato et al ASH 2022


BRUIN 1/2: PFS



Mato et al. N Engl J Med. 2023.


Progression-Free Survival in CLL/SLL Subgroups






Mato et al ASH 2022

Diverse BTK mutations cause resistance to non- covalent BTKi



Montoya et al ASH 2022


ACQUIRED RESISTANCE TO PIRTOBRUTINIB MOSTLY CONVERGES AROUND ON-TARGET *BTK* MUTATIONS



- Most (71% [35/49]) patients had at least 1 acquired mutation at progression
- ► There were a total of 82 acquired mutations in 3 patients

*Others: APC, ATM, CDKN2A, CDKN2B, EP300, ERBB3, IRF4, KIT, KMT2C, NOTCH1, NRAS, NTRK1, PIK3CG, RB1, SMARCA4, TNFAIP3, XPO1. Source: Brown et al. Abstract \$146, EHA 2023.


PIRTOBRUTINIB: BTKi ACQUIRED MUTATIONS



- Decrease/clearance of C481 clones observed at progression on pirtobrutinib in 92% (22/24) of patients
- BTK C481R/S/Y, T474, L528, other kinase mutations arose at/near progression (n=27 patients)
- ORRs were similar across groups regardless of the acquired BTK mutation


BTKi, Bruton tyrosine kinase inhibitor; ORR, overall response rate; PD, progressive disease; VAF, variant allele frequency. Source: Brown et al. Abstract \$146, EHA 2023.

Not All BTK Mutations Are Equal: Concept of Kinase-Dead Mutations



- C481S mutations retain the kinase activity of BTK and can be successfully targeted with non-covalent BTK inhibitors like pirtobrutinib
- On the other hand, mutations such as L528W will lead to a kinase dead (or PLCγ2 independent) BTK that acts as a scaffold protein for other components of the BCR pathway.
- Both covalent and non-covalent BTKi that target the kinase domain will be ineffective in this setting.

NX-2127: first-in-class targeted protein degrader of BTK



Montoya et al ASH 2022

A First-in-Human Trial of NX-2127, a BTK Degrader, in R/R CLL and **B-Cell Malignancies**

≥ 2 prior line	of therapy (median 6) BTKi, 77% post Ven), Dose	NX-212 escalation: 100, 200, 30	
able 1. Summary of treatment-er including patients with CLL and N		s (TEAEs) occurring ir	n >15% of all patients	Figure 1. CLL patient disposition
Preferred Term	All Grades (N=26)	Grade ≥ 3 (N=26)	Grade ≥ 3 Related (N=26)	2127-001 Time on Treatment (months*)
Any AE	25 (96%)	15 (58%)	12 (46%)	\rightarrow
Fatigue	16 (62%)	0 (0%)	0 (0%)	\rightarrow
Neutrophil Count Decrease	10 (39%)	9 (35%)	9 (35%)	\rightarrow
Anemia	7 (27%)	4 (15%)	2 (8%)	
Contusion	7 (27%)	0 (0%)	0 (0%)	
Hypertension	7 (27%)	1 (4%)	1 (4%)	
Dyspnoea	5 (19%)	1 (4%)	0 (0%)	
Pruritis	5 (19%)	0 (0%)	0 (0%)	
Rash maculo-papular	5 (19%)	0 (0%)	0 (0%)	PD
Blood creatinine increased	4 (15%)	0 (0%)	0 (0%)	AE
COVID-19	4 (15%)	1 (4%)	0 (0%)	Disc. Due to >7 days missed doses
Diarrhea	4 (15%)	0 (0%)	0 (0%)	AE
Petechiae	4 (15%)	0 (0%)	0 (0%)	Disc. Due to subject choice $ ightarrow m Ong table $
Platelet count decreased	4 (15%)	1 (4%)	0 (0%)	0 1 2 3 4 5 6 7 8 9 10 11 12 13
				Month *

Data Extract Date is 30JUN2022. Data Cutoff Date is 16JUN2022.

*Month is defined as a duration of 28 days, which is equivalent to a treatment cycle for NX-2127


Program: B:WREXD1\Biostats\NX:2127\NX:2127\NX:2127-001\ash2022q3\Outputs\TLFs\@GMSY swim.sas Source: a.ads1r.exps.ds.eot 29JUL22:13:33

NX-2127: Response in BTKi Exposed Patients

Disease-evaluable patients	n=15				
Objective response rate, ^a % (95% CI)	33 (12–62)				
Best response, n (%)					
CR	0 (0)				
PR	5 (33.3)				
SD	5 (33.3)				
PD	2 (13.3)				
NE ^b	3 (20)				

^aObjective response rate includes CR + CRi + nPR + PR-L + PR

^bPatients who discontinued after a single assessment of SD are considered as NE



*One patient, not shown above, with prior BTKi and BCL2i treatment and with a *BTK* mutation detected at baseline, had no nodal disease at baseline. Their treatment is ongoing with a PR

Conclusions

- Patient preferences and Individualized therapy should be taken into consideration to choose between fixed duration or tx until progression.
- Great options for front line CLL: Long term therapy
 - First generation **ibrutinib** show great long term efficacy supported by multiple Phase III trials as well data for del17p/TP53 more discontinuation for AEs.
 - Second gen BTKi, acalabrutinib also showing excellent data with better tolerability.
 - Zanubrutinib now approved with great data in front line and good tolerability.
- Great options for front line CLL: Fixed duration
 - **Obinutuzumab+venetoclax**: great efficacy with deep MRD responses.
 - Ibrutinib+venetoclax: approved in EU.
 - Triple therapies trials ongoing but unclear benefits.
- Relapsed/Refractory CLL
 - BTK mutational profile is an important tool to define BTKi sequencing
 - Pirtobrutinib soon to be an option in CLL but already approved in MCL
 - Others non covalent inhibitors on their way.
 - Protein degraders entering Phase I/II
 - CART pending evaluation in a Phase III